scispace - formally typeset
C

Circe Mesa

Researcher at Center of Molecular Immunology

Publications -  37
Citations -  2330

Circe Mesa is an academic researcher from Center of Molecular Immunology. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 18, co-authored 32 publications receiving 2061 citations.

Papers
More filters
Journal ArticleDOI

Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor

TL;DR: Adoptive transfer of tumor antigen-specific CD8(+) T lymphocytes resulted in therapy of established tumors only in mice lacking C/EBPbeta in the myeloid compartment, suggesting that C/ EBPbeta is a critical regulator of the immunosuppressive environment created by growing cancers.
Journal ArticleDOI

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF

TL;DR: In vitro assays unveil a hierarchy of immunoregulatory activity among MDSC subsets that is controlled by tumor‐released GM‐CSF, and Gene silencing experiments indicated that GM‐ CSF was necessary to induce preferential expansion of both CD11b+/Gr‐1int and CD11B+/ Gr‐1low subsets in the spleen of tumor‐bearing mice and mediate tumor‐induced tolerance.
Journal ArticleDOI

A Mouse IgG1 Monoclonal Antibody Specific for N-Glycolyl GM3 Ganglioside Recognized Breast and Melanoma Tumors

TL;DR: Immunohistochemical studies in fresh tumor tissues showed that 14F7 MAb strongly recognized in antigen expressed in human breast and melanoma tumors.
Journal ArticleDOI

Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).

TL;DR: The immunological and physicochemical properties of very small size proteoliposomes (VSSP) obtained by using anionic detergents to incorporate gangliosides into the outer membrane protein complex (OMPC) of N. meningitidis are reported.
Journal ArticleDOI

Challenges facing adjuvants for cancer immunotherapy.

TL;DR: The present review discusses the role of cancer adjuvants at the different phases of the generation of antitumour immunity following vaccination.